GlassScriptPhysician profile
Gloria Mireles
NPI 1538596531
$4,669.05
in general payments reported to CMS, 2019-2025
25 companies · $624 in 2025
The $624 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $286 · 2020: $231 · 2021: $338 · 2022: $1,273 · 2023: $874 · 2024: $1,043 · 2025: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,524 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,524.25 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,095.10 | 2021-2025 | |
| Medtronic, INC. | $782.16 | 2021-2025 | Percept PC Brainsense |
| Sk Life Science, INC. | $387.01 | 2021-2025 | |
| Ucb, INC. | $337.48 | 2021-2024 | Briviact |
| Sumitomo Pharma America, INC. | $258.17 | 2023-2024 | Aptiom |
| Acadia Pharmaceuticals INC | $194.67 | 2020-2024 | Nuplazid |
| Pfizer INC. | $187.81 | 2023-2024 | |
| Neurocrine Biosciences, INC. | $173.45 | 2022-2024 | Ingrezza, Ongentys |
| Biohaven Pharmaceutical Holding Company LTD. | $172.37 | 2022 | |
| Lilly USA, LLC | $162.80 | 2019-2023 | Emgality |
| Amgen INC. | $157.85 | 2023-2025 | Aimovig |
| Sunovion Pharmaceuticals INC. | $148.93 | 2019 | |
| Allergan, INC. | $122.91 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $104.56 | 2024 | Xdemvy |
| Catalyst Pharmaceuticals, INC. | $81.67 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $67.04 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $46.67 | 2020-2022 | |
| Lundbeck LLC | $39.18 | 2024-2025 | Vyepti, Rexulti |
| Otsuka America Pharmaceutical, INC. | $35.96 | 2023-2024 | Rexulti |
| Upsher-Smith Laboratories LLC | $29.38 | 2020 | |
| Mdd US Operations, LLC | $22.40 | 2021 | |
| Arbor Pharmaceuticals, INC. | $18.28 | 2020 | |
| Biogen, INC. | $15.92 | 2021 | |
| Avion Pharmaceuticals | $14.52 | 2023 | Dhivy |
| Adamas Pharmaceuticals, INC. | $12.76 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gloria Mireles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.